Would you offer adjuvant olaparib to a male patient with HR+, HER2- T2N0 breast cancer with a BRCA2 germline mutation following mastectomy who is not a candidate for adjuvant chemotherapy?  

Will offer brief thoughts but welcome others as well. First, I think it would be helpful to know what risk stratification has been done to decide the patient should be offered chemotherapy and not just endocrine therapy. Also, it would be useful to know why they are not a candidate for chemotherapy ...

BRCA2 mutations are the most common familial genetic alteration in men with breast cancer and this is not an entirely unusual scenario. The first question I would ask here is, how it was decided that this patient needs adjuvant chemotherapy? In a man with breast cancer, Oncotype recurrence scor...